Ghana vs Zambia: Average cost of drugs for extensively drug-resistant tuberculosis
Ghana
800 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
Ghana rank
47th
Zambia rank
49th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Ghana
- Zambia
How they compare
Ghana currently reports 800 constant 2022 US$ against 600 constant 2022 US$ in Zambia, a difference of 200 constant 2022 US$.
That makes Ghana's figure about 1.3 times Zambia's.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was Zambia ahead.
Ghana ranks 47th and Zambia ranks 49th of 56 countries.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ghana | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 6,240 constant 2022 US$ | 4,240 constant 2022 US$ | Zambia |
| 2020s | 1,526 constant 2022 US$ | 3,816 constant 2022 US$ | 2,290 constant 2022 US$ | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Ghana or Zambia?
- Ghana, at 800 constant 2022 US$ against 600 constant 2022 US$ in Zambia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Ghana and Zambia?
- 200 constant 2022 US$, with Ghana ahead.
- How many years of comparable data are there for Ghana and Zambia?
- 7 years are reported by both, from 2018 to 2024.
- How do Ghana and Zambia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Ghana ranks 47th and Zambia ranks 49th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.